Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
ANGLE logo — The leading experts in cancer cell capture and analysis from...

ANGLE

The leading experts in cancer cell capture and analysis from liquid biopsies

Founded 1994 United Kingdom United Kingdom 165 employees Post-IPO Equity Total: $29.68M Biotechnology, Health Care +1

General Information

Company Name ANGLE
Founded Year 1994
Location United Kingdom United Kingdom
Employees 165
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with ANGLE. To contact ANGLE, visit angleplc.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ANGLE compare?

A PDF of ANGLE and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ANGLE soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ANGLE

ANGLE, the leading experts in cancer cell capture and analysis from liquid biopsies, is a world-leading liquid biopsy company specializing in innovative circulating tumor cell (CTC) diagnostic solutions. ANGLE's FDA cleared and patent-protected circulating tumor cell (CTC) harvesting technology, the Parsortix® PC1 System, allows complete downstream analysis of the sample, including whole cell imaging and proteomic analysis, as well as full genomic and transcriptomic molecular analysis, using a simple blood sample. The company's commercial businesses focus on diagnostic products such as the Parsortix® system and associated consumables, as well as clinical services offered through GCP-compliant laboratories in the UK and the United States. These services encompass custom-made assay development and clinical trial testing for the pharmaceutical industry. With over 80 peer-reviewed publications demonstrating the performance of the Parsortix system, ANGLE stands as a pioneering force in the biotechnology and healthcare industries, striving to make a substantial impact in research, drug development, and clinical oncology. Founded in 1994 and headquartered in the United Kingdom, the company recently secured a noteworthy £9.30M post-IPO equity investment on 05 June 2024. For more information, visit www.angleplc.com.

Business keywords: Liquid Biopsy, Circulating Tumor Cells, Medical Device Manufacturer, Microfluidics, CTC Diagnostic Solutions, FDA Cleared Technology, Parsortix System, Clinical Oncology, Diagnostic Products, Cancer Diagnostics, Fetal Health, Medical Technologies, Research and Development, Commercialization

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity £9.30M -
05 Jun 2024
Post IPO Equity £20.13M -
15 Jul 2022
Venture Round $250.00K -
27 Mar 2015

ANGLE Alternatives & Competitors

View All Alternatives
ANGLE vs
Vortex Biosciences
Vortex Biosciences United States

Circulating Tumor Cells (CTCs) are cancer cells, which have detached from the primary tumor and have...

Venture round
7 employees
Biotechnology, Health Care
ANGLE vs
Cellsway
Cellsway United Kingdom

Liquid biopsy for cancer monitoring through isolation and counting Circulating Tumor Cells (CTCs) fr...

5 employees
Biotechnology, Health Care
ANGLE vs
SmartCatch
SmartCatch France

For a reliable liquid biopsy accessible to everyone

Seed
19 employees
Health Care, Health and Wellness
View all alternatives

FAQ About ANGLE

The leading experts in cancer cell capture and analysis from liquid biopsies
ANGLE was founded in 1994.
ANGLE is headquartered in United Kingdom.
ANGLE operates in Biotechnology, Health Care and Medical Devices. Its work centres on Liquid Biopsy, Circulating Tumor Cells, Medical Device Manufacturer and Microfluidics.
ANGLE has approximately 165 employees.
ANGLE has completed 3 funding rounds, raising a total of $29.68M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to ANGLE include Vortex Biosciences, Cellsway, SmartCatch, Capio Biosciences, RareCyte, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ANGLE and Vortex Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ANGLE, https://www.bouncewatch.com/company/angle, updated 5 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout